ContraFect’s Path Forward Gets Murky With Exebacase Trial Failure

 
• By Alaric DeArment
  
ContraFect said it stopped its Phase III trial of exebacase in MRSA for futility • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D